4,7-Bis(5-bromothiophen-2-yl)-5,6-bis(octyloxy)benzo[c][1,2,5]oxadiazole

Catalog No. :
ACTVSR790
CAS No. :
1314801-37-0
Molecular Formula :
C30H38Br2N2O3S2
Molecular Weight :
698.59

IUPAC Name:4,7-bis(5-bromothiophen-2-yl)-5,6-bis(octyloxy)benzo[c][1,2,5]oxadiazole

4,7-Bis(5-bromothiophen-2-yl)-5,6-bis(octyloxy)benzo[c][1,2,5]oxadiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4,7-Bis(5-bromothiophen-2-yl)-5,6-bis(octyloxy)benzo[c][1,2,5]oxadiazole
IUPAC Name4,7-bis(5-bromothiophen-2-yl)-5,6-bis(octyloxy)benzo[c][1,2,5]oxadiazole
Molecular FormulaC30H38Br2N2O3S2
Molecular Weight698.59
SMILESCCCCCCCCOC1=C(C2=CC=C(Br)S2)C3=NON=C3C(C4=CC=C(Br)S4)=C1OCCCCCCCC
InChI KeyYTEXMHBTLUADJK-UHFFFAOYSA-N
Synonym4,7-Bis(5-bromothiophen-2-yl)-5,6-bis(octyloxy)benzo[c ][1,2,5] oxadiazole;2,1,3-Benzoxadiazole, 4,7-bis(5-bromo-2-thienyl)-5,6-bis(octyloxy)-
CAS No.1314801-37-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACTVSR790 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTVSR790 route product structure diagram
    ACTVSR7901314801-37-0
Inquiry

2. ACTVSR790 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACDSFK509 route compound structure diagram
    ACDSFK509629-27-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTVSR790 route product structure diagram
    ACTVSR7901314801-37-0
Inquiry

Comments (0)